Overall, our results demonstrated that DFO and EDA brought great benefits to prostatitis treatment via inhibiting ferroptosis, accompanied by the reduction of inflammation, fibrosis, and mast cell activation, which was partly attributed to the reactivation of the NRF2/HO-1 signaling. Here, NFE2L2 is linked to urogenital neoplasm.